These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 21362200)

  • 1. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse ER+/PIK3CA
    Stratikopoulos EE; Kiess N; Szabolcs M; Pegno S; Kakit C; Wu X; Poulikakos PI; Cheung P; Schmidt H; Parsons R
    Oncogene; 2019 Jan; 38(1):47-59. PubMed ID: 30076411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
    Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
    Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
    Brufsky AM
    Breast J; 2014; 20(4):347-57. PubMed ID: 24861776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
    Bhola NE; Jansen VM; Bafna S; Giltnane JM; Balko JM; Estrada MV; Meszoely I; Mayer I; Abramson V; Ye F; Sanders M; Dugger TC; Allen EV; Arteaga CL
    Cancer Res; 2015 Jan; 75(2):405-14. PubMed ID: 25480943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
    Brett JO; Spring LM; Bardia A; Wander SA
    Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer.
    Patani N; Dunbier AK; Anderson H; Ghazoui Z; Ribas R; Anderson E; Gao Q; A'hern R; Mackay A; Lindemann J; Wellings R; Walker J; Kuter I; Martin LA; Dowsett M
    Clin Cancer Res; 2014 Aug; 20(15):3962-73. PubMed ID: 24916694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
    Spoerke JM; Gendreau S; Walter K; Qiu J; Wilson TR; Savage H; Aimi J; Derynck MK; Chen M; Chan IT; Amler LC; Hampton GM; Johnston S; Krop I; Schmid P; Lackner MR
    Nat Commun; 2016 May; 7():11579. PubMed ID: 27174596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of estrogen receptor down-regulators for endocrine resistant breast cancer.
    Li Y; Orahoske CM; Urmetz SM; Zhang W; Huang Y; Gan C; Su B
    J Steroid Biochem Mol Biol; 2022 Nov; 224():106162. PubMed ID: 35932957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
    Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
    Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in
    Ippen FM; Alvarez-Breckenridge CA; Kuter BM; Fink AL; Bihun IV; Lastrapes M; Penson T; Schmidt SP; Wojtkiewicz GR; Ning J; Subramanian M; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
    Clin Cancer Res; 2019 Jun; 25(11):3374-3383. PubMed ID: 30796030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
    Belli S; Esposito D; Ascione CM; Messina F; Napolitano F; Servetto A; De Angelis C; Bianco R; Formisano L
    Cancer Lett; 2024 Jul; 593():216968. PubMed ID: 38788968
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Drago JZ; Formisano L; Juric D; Niemierko A; Servetto A; Wander SA; Spring LM; Vidula N; Younger J; Peppercorn J; Yuen M; Malvarosa G; Sgroi D; Isakoff SJ; Moy B; Ellisen LW; Iafrate AJ; Arteaga CL; Bardia A
    Clin Cancer Res; 2019 Nov; 25(21):6443-6451. PubMed ID: 31371343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
    Weigelt B; Warne PH; Lambros MB; Reis-Filho JS; Downward J
    Clin Cancer Res; 2013 Jul; 19(13):3533-44. PubMed ID: 23674493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of the relevance of PI3K pathway in HR-positive breast cancer.
    Vasan N; Toska E; Scaltriti M
    Ann Oncol; 2019 Dec; 30(Suppl_10):x3-x11. PubMed ID: 31859348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
    Kashiyama T; Oda K; Ikeda Y; Shiose Y; Hirota Y; Inaba K; Makii C; Kurikawa R; Miyasaka A; Koso T; Fukuda T; Tanikawa M; Shoji K; Sone K; Arimoto T; Wada-Hiraike O; Kawana K; Nakagawa S; Matsuda K; McCormick F; Aburatani H; Yano T; Osuga Y; Fujii T
    PLoS One; 2014; 9(2):e87220. PubMed ID: 24504419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.
    Chen JW; Jacot W; Cortés J; Krop IE; Dent S; Harbeck N; De Laurentiis M; Diéras V; Im YH; Stout TJ; Schimmoller F; Savage HM; Hutchinson KE; Wilson TR
    Mol Oncol; 2023 Oct; 17(10):2000-2016. PubMed ID: 36892268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
    Lawson M; Cureton N; Ros S; Cheraghchi-Bashi A; Urosevic J; D'Arcy S; Delpuech O; DuPont M; Fisher DI; Gangl ET; Lewis H; Trueman D; Wali N; Williamson SC; Moss J; Montaudon E; Derrien H; Marangoni E; Miragaia RJ; Gagrica S; Morentin-Gutierrez P; Moss TA; Maglennon G; Sutton D; Polanski R; Rosen A; Cairns J; Zhang P; Sánchez-Guixé M; Serra V; Critchlow SE; Scott JS; Lindemann JPO; Barry ST; Klinowska T; Morrow CJ; Carnevalli LS
    Cancer Res; 2023 Dec; 83(23):3989-4004. PubMed ID: 37725704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
    Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
    Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
    Jayaraman S; Hou X; Kuffel MJ; Suman VJ; Hoskin TL; Reinicke KE; Monroe DG; Kalari KR; Tang X; Zeldenrust MA; Cheng J; Bruinsma ES; Buhrow SA; McGovern RM; Safgren SL; Walden CA; Carter JM; Reid JM; Ingle JN; Ames MM; Hawse JR; Goetz MP
    Breast Cancer Res; 2020 May; 22(1):51. PubMed ID: 32430040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.